Episode

ProLivRx: A New Approval in Depression

Podcast: The Carlat Psychiatry Podcast
Published: Jan 19, 2026
Duration seconds: 1250
Processing state: not_requested
Canonical source: https://www.thecarlatreport.com/blogs/2-the-carlat-psychiatry-podcast/post/5826-prolivrx-a-new-approval-in-depression
Audio: https://media.blubrry.com/the_carlat_psychiatry_podcast/content.blubrry.com/the_carlat_psychiatry_podcast/A_New_Approval_for_Depression_Edit_V2.mp3
JSON: /v1/public/podcasts/the-carlat-psychiatry-podcast-491560/episodes/prolivrx-a-new-approval-in-depression
Markdown: /podcast/the-carlat-psychiatry-podcast-491560/prolivrx-a-new-approval-in-depression.md

Actions

POST https://stenobird.com/v1/public/podcasts/the-carlat-psychiatry-podcast-491560/episodes/prolivrx-a-new-approval-in-depression/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/the-carlat-psychiatry-podcast-491560/prolivrx-a-new-approval-in-depression.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

We interview Linda Carpenter, lead investigator on the new FDA approved device for difficult-to-treat depression. CME: Take the CME Post-Test for this Episode Published On: 01/19/2026 Duration: 20 minutes, 49 seconds Chris Aiken, MD and Kellie Newsome, PMHNP have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.